This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Biothrax
Generic Name
Anthrax vaccine
DrugBank Accession Number
DB11003
Background

Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in at high risk of, suspected or confirmed exposure to Bacillus anthracis. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium [FDA Label].

Type
Biotech
Groups
Approved
Biologic Classification
Vaccines
Other vaccines
Synonyms
  • Anthrax vaccine adsorbed
  • Bacillus anthracis inactivated antigen
  • Bacillus anthracis strain V770-NP1-R antigen
  • Bacillus anthracis strain V770-NP1-R antigens
  • Bacillus anthracis strain V770-NP1-R filtrate (attenuated) antigen
  • Bacillus anthracis strain V770-NP1-R filtrate antigen
External IDs
  • RPA102

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Abacavir.
AbataceptThe risk or severity of infection can be increased when Anthrax vaccine is combined with Abatacept.
AcyclovirThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Acyclovir.
AdalimumabThe risk or severity of infection can be increased when Anthrax vaccine is combined with Adalimumab.
Adefovir dipivoxilThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Adefovir dipivoxil.
AldesleukinThe risk or severity of infection can be increased when Anthrax vaccine is combined with Aldesleukin.
AlefaceptThe risk or severity of infection can be increased when Anthrax vaccine is combined with Alefacept.
AlemtuzumabThe risk or severity of infection can be increased when Anthrax vaccine is combined with Alemtuzumab.
AltretamineThe risk or severity of infection can be increased when Anthrax vaccine is combined with Altretamine.
AmantadineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Amantadine.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
BioThraxSuspension50 mcg / 0.5 mLIntramuscular; SubcutaneousEmergent Biodefense Operations Lansing LlcNot applicableNot applicableCanada flag
BioThraxInjection, suspension100 ug/1mLIntramuscular; SubcutaneousEmergent BioDefense Operations Lansing, LLC1970-11-04Not applicableUS flag

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
873OI62848
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347911075
RxNav
404774
Wikipedia
Anthrax_vaccine
FDA label
Download (363 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedPreventionBacillus Anthracis (Anthrax)1
4CompletedPreventionHealthy Subjects (HS)1
3CompletedPreventionAnthrax1
3CompletedTreatmentAnthrax1
2CompletedPreventionAnthrax3
2CompletedTreatmentAnthrax1
2TerminatedPreventionBacillus Anthracis (Anthrax)1
1Active Not RecruitingPreventionAnthrax1
1Active Not RecruitingPreventionHealthy Subjects (HS)1
1CompletedPreventionAnthrax1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, suspensionIntramuscular; Subcutaneous
Injection, suspensionIntramuscular; Subcutaneous100 ug/1mL
SuspensionIntramuscular; Subcutaneous50 mcg / 0.5 mL
Injection, suspensionIntramuscular50 mcg/dose
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at December 01, 2015 20:05 / Updated at June 12, 2020 17:42